Q3 2025 Earnings Forecast for AstraZeneca PLC Issued By Zacks Research (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) – Investment analysts at Zacks Research lifted their Q3 2025 earnings per share estimates for shares of AstraZeneca in a research report issued on Wednesday, August 28th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.17 for the quarter, up from their previous forecast of $1.15. The consensus estimate for AstraZeneca’s current full-year earnings is $4.06 per share.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.01. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter in the prior year, the company posted $1.08 earnings per share. AstraZeneca’s revenue was up 9.1% compared to the same quarter last year.

AZN has been the subject of a number of other reports. Barclays raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Argus raised their price objective on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Finally, The Goldman Sachs Group assumed coverage on AstraZeneca in a research note on Thursday, May 30th. They set a “buy” rating and a $97.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Down 0.1 %

AZN opened at $87.30 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The stock has a market cap of $270.68 billion, a price-to-earnings ratio of 42.79, a PEG ratio of 1.63 and a beta of 0.45. The company’s 50-day moving average price is $80.64 and its two-hundred day moving average price is $74.63. AstraZeneca has a twelve month low of $60.47 and a twelve month high of $87.62.

AstraZeneca Cuts Dividend

The business also recently disclosed a Semi-Annual dividend, which will be paid on Monday, September 9th. Shareholders of record on Friday, August 9th will be paid a dividend of $0.49 per share. The ex-dividend date of this dividend is Friday, August 9th. This represents a yield of 1.8%. AstraZeneca’s payout ratio is currently 48.04%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. GHP Investment Advisors Inc. bought a new stake in shares of AstraZeneca during the second quarter worth $26,000. Able Wealth Management LLC purchased a new position in AstraZeneca during the fourth quarter valued at approximately $27,000. Pathway Financial Advisers LLC bought a new stake in AstraZeneca during the first quarter valued at about $29,000. Pin Oak Investment Advisors Inc. raised its stake in shares of AstraZeneca by 468.4% during the 4th quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after acquiring an additional 370 shares in the last quarter. Finally, RFP Financial Group LLC lifted its holdings in shares of AstraZeneca by 56.3% during the 1st quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after purchasing an additional 178 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.